A 2-Year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Alendronic acid (Primary) ; Ibandronic acid (Primary) ; Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Acronyms TRIO
- 02 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 06 May 2011 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.